CME providers to pay more to be monitored
Executive Summary
To finance tighter oversight of continuing medical education programs, the Accreditation Council for Continuing Medical Education is phasing in higher accreditation fees over the next three years. Initial increases will occur in 2009, including a special assessment that could be as high as $7,000, depending on an accredited provider's reported expenses. CME is a major component in the debate about industry influence on physicians' prescribing patterns, prompting Pfizer to curtail its support for CME and ACCME to propose limits on industry funding (1"The Pink Sheet," Sept. 29, 2008, p. 18)
You may also be interested in...
Industry-Funded CME To Go Way Of Dinosaurs? ACCME Comments Lumber In
The pharmaceutical industry continues to retrench how it provides continuing medical education in response to public and congressional pressure, but firms are also marshalling for a fight against an outright ban
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.